Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04193020
Other study ID # ST-859
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2020
Est. completion date January 1, 2026

Study information

Verified date April 2021
Source Wroclaw Medical University
Contact Joanna Przezdziecka-Dolyk, PhD
Phone +49605693022
Email joanna.przezdziecka-dolyk@umed.wroc.pl
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Acute and chronic inflammatory eye diseases are difficult to diagnose and maintain quiescent with therapy. Proposed study is aimed to find on the one hand, novel factors for recurrence of the disease or remission of inflammation and evaluation of the impact of lifestyle and known factors on the other. Each patient is treated in accordance to the best of medical knowledge and guidelines for each disease. This prospective cohort study will enroll uveitic patients to the steroid only group (SG), combined (steroid and adjuvant drug) group (CG) or bilogic therapy group (BTG). At baseline, patient data are recorded using patient-reported outcome measures and clinical assessments (ophthalomology) on disease activity (clinical scales), quality of life, and lifestyle together with registry data on comorbidity and medication. During follow-up evaluation of a successful treatment outcome response will be based on clinical scales and most frequently used primary endpoints; the major outcome of the analyses will be to detect differences in treatment outcome between patients in different treatment group.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date January 1, 2026
Est. primary completion date January 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - new diagnosis of uni or bilateral uveitis - recurrence of the diagnosed previously uni or bilateral uveitis Exclusion Criteria: - not mentally able to reply the questionnaire

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Surveillance card
Surveillance card and additional examination to find novel markers and better assess the existing ones

Locations

Country Name City State
Poland Department of Ophthalmology Wroclaw

Sponsors (2)

Lead Sponsor Collaborator
Wroclaw Medical University Wroclaw University of Science and Technology

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Other COVID-19 confirmed infection asymptomatic patient PCR-positive result of COVID-19 specific testing, no treatment required 1 year
Other COVID-19 confirmed infection PCR-positive result of COVID-19 specific testing, patient require treatment. The mode of treatment will be recorded into several groups: 1) antibiotics, 2) antivirals, 3) biologic treatment, 4) immunoglobulins, 5) steroids 1 year
Other COVID-19 related acute respiratory distress syndrome (ARDS) COVID-19 related acute respiratory distress syndrome (ARDS). Situation in which patients need any of described below: 1) supportive oxygen therapy, 2) non-invasive ventilation, 3) invasive/ mechanical ventilation, 4) use of ECMO, 5) admission to intensive care unit, 6) dialysis 1 year
Other Ocular Surface Disease Index Ocular Surface Disease Index (OSDI) questionaire results are used to define if during the course of the disease the dry eye syndrom occurs. Used with subclasses describing the vision-related functions, ocular symptoms, environmental triggers 1 year
Other Dry Eye Questionnaire Dry Eye Questionnaire (DEQ 5) questionaire results are used to define if during the course of the disease the dry eye syndrom occurs. Used with subscales describing the eye dyscomfort, eye dryness and watery eyes. 1 year
Other SANDE Questionnaire SANDE Questionnaire that assess the frequency and severity of symptoms during the treatment. 1 year
Other LIKERT Questionnaire LIKER Questionnaire that assess the frequency, severity of symptoms and infuence of symptoms on the patient day-to-day activities during the treatment. 1 year
Other LIPCOF scale Assesment of conjunctival folds according to pre-defined scale. 1 year
Other OXFORD scale OXFORD scale conducted with instalation of 2 microliters of 2% fluorescite into the conjunctival sac and assessment according to the pre-defined scale. The subscales for nasal, temporal and lower lid conjunctiva as well as for cornea was used. The scale has been conducted during the treatment period and if necessary during additional visits. 1 year
Other SICCA scale SICCA scale conducted with instalation of 2 microliters of 2% fluorescite into the conjunctival sac and assessment of cornea according to the pre-defined scale. Different dye was used for conjunctica (lizamine green). The subscales for nasal and temporal conjunctiva as well as for cornea was used. The scale has been conducted during the treatment period and if necessary during additional visits. 1 year
Primary Treatment success Total number of treatment success in each group 1 year
Primary Recurrence time Time to the next recurrence after the treatment regimen introduction 10 years
Primary Severe visual loss Time and cause of severe visual loss 10 years
Secondary ETDRS Visual Acuity Visual Acuity will be performed with ETDRS charts different for right and left eye 10 years
Secondary The SUN working group grading system for anterior chamber cells At each visit anterior chamber will be examined to assess anterior chamber cells (1mm x 1mm slit beam in height and width, when thrown at an angle of 45-60°). The recorded number of cells will be used to determine the grade according to the SUN criteria. 10 years
Secondary The SUN working group grading system for anterior chamber flare At each visit anterior chamber will be examined to assess anterior chamber flare (1mm x 1mm slit beam in height and width, when thrown at an angle of 45-60°). The observed changes will be used to determine the grade according to the SUN criteria. 10 years
Secondary AREDS 2008 Clinical Lens Opacity Grading Procedure Using AREDS system for classifying cataracts from photographs: AREDS Report No. 4 the lens opacity will be graded. 10 years
Secondary NIH grading system for vitreous cells At each visit vitreous will be examined to assess vitreous cells (1mm x 3mm slit beam in anterior vitreous). The recorded number of cells will be used to determine the grade according to the NIH criteria. 10 years
Secondary NIH grading system for vitreous haze At each visit vitreous will be examined to assess vitreous haze. The recorded of clarity of posterior pole funduscopy will be used to determine the grade according to the NIH criteria. 10 years
Secondary Submacular choroidal thickness OCT EDI recordings processed with developed by researchers methodology for image processing. 10 years
See also
  Status Clinical Trial Phase
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Active, not recruiting NCT04704609 - Imaging Quantification of Inflammation (IQI)
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Withdrawn NCT01280669 - Intravitreal Sirolimus as Therapeutic Approach to Uveitis Phase 2
Terminated NCT02907814 - Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography N/A
Active, not recruiting NCT02252328 - Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients Phase 2/Phase 3
Completed NCT04183387 - Simvastatin in Uveitis Phase 2
Completed NCT01983488 - Clinical Outcome in Uveitis
Withdrawn NCT00499551 - A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis Phase 1/Phase 2
Completed NCT00132691 - Multicenter Uveitis Steroid Treatment (MUST) Trial Phase 4
Terminated NCT00114062 - Study to Treat Uveitis Associated Macular Edema Phase 2
Completed NCT00476593 - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications N/A
Completed NCT00001867 - Effect of Pregnancy on Uveitis N/A
Completed NCT00379275 - Eye and Immunogenetic Features of Sarcoidosis N/A
Active, not recruiting NCT03828019 - Adalimumab vs. Conventional Immunosuppression for Uveitis Trial Phase 3
Terminated NCT01939691 - Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Phase 4
Active, not recruiting NCT03889860 - Objective Choroidal Thickness Measurements in Uveitis
Completed NCT00070759 - Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis Phase 2
Recruiting NCT05486468 - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Phase 3
Active, not recruiting NCT05385757 - UNICORNS: Uveitis in Childhood Prospective National Cohort Study